Lead Product(s) : LNS8801
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : National Cancer Institute
Deal Size : $2.0 million
Deal Type : Funding
Linnaeus Wins Fourth NCI SBIR Grant, Total SBIR Funding Reaches $8.3M
Details : The fund will support the clinical development of its lead compound, LNS8801, which targets a G protein-coupled receptor (GPER), for the treatment of metastatic cutaneous melanoma.
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 26, 2025
Lead Product(s) : LNS8801
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : National Cancer Institute
Deal Size : $2.0 million
Deal Type : Funding
Lead Product(s) : LNS8801
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNS8801 is an oral specific and potent agonist of GPER whose activity is dependent on the expression of GPER. GPER activation depletes c-Myc protein levels rapidly and durably. LNS8801 displays potent antitumor activities and inducing immune memory.
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : LNS8801
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNS8801 is an orally bioavailable and highly specific and potent agonist of GPER whose activity is dependent on the expression of GPER. In preclinical cancer models, LNS8801 displays potent antitumor activities across a wide range of tumor types.
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The combination of LNS8801 with pembrolizumab has demonstrated strong signals of activity in patients with metastatic cancer who had previously benefited from and then developed secondary resistance to ICI therapy.
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2022
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNS8801 is an orally bioavailable and highly specific and potent agonist of GPER whose activity is dependent on the expression of GPER. GPER activation by LNS8801 rapidly and durably depletes c-Myc protein levels.
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2021
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : For the first time, any company has dosed a patient in a clinical trial specifically targeting the G protein-coupled estrogen receptor, in combination with pembrolizumab. LNS8801 is an orally bioavailable small molecule that is a highly specific and pote...
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNS8801
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The authors also demonstrated that GPER protein can be detected in a large percentage of clinical specimens, suggesting that GPER may represent a new therapeutic target for PDAC.
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2020
Lead Product(s) : LNS8801
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Linnaeus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Collaboration agreement aims to study the combination of Linnaeus's lead investigational drug candidate LNS8801, and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with selected advanced solid tumors.
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 23, 2020
Lead Product(s) : LNS8801,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Linnaeus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or after anti–programmed cell death receptor or ligand (anti–PD-1/L1)...
Product Name : LNS8801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2020